Congratulations to Trogenix on emerging from stealth mode! As an AIN Ventures portfolio company, we look forward to supporting Ken Macnamara and Steve Pollard in their mission to revolutionize cancer treatment. More below. . . . Congrats!
We are excited to announce that Trogenix has emerged from stealth today, unveiling our breakthrough Synthetic Super-Enhancer (SSE) platform, Odysseus, for treating aggressive cancers: https://lnkd.in/eGJqM5H8 Founded by our CSO Steve Pollard and 4BIO Capital as a spinout from The University of Edinburgh, and led by CEO Ken Macnamara, Trogenix brings together synthetic biology, machine learning, gene therapy and precision targeting technologies to transform cancer treatment, from chronic disease management to potentially curative one-time treatments. Thank you to our investors 4BIO Capital, IQ Capital, Cancer Research Horizons, National Brain Tumor Society, AIN Ventures and Old College Capital for their support in our mission to revolutionise cancer treatment. #CancerResearch #Glioblastoma #Immunotherapy #GeneTherapy #SyntheticBiology #LifeSciences #Innovation
